Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. KalVista Pharmaceuticals Inc shares valued at $120,424 were sold by Palleiko Benjamin L on Dec 08 ’25. At $16.51 per share, Palleiko Benjamin L sold 7,294 shares. The insider’s holdings dropped to 424,520 shares worth approximately $6.35 million following the completion of this transaction.
Also, Sweeny Nicole sold 3,813 shares, netting a total of over 51,289 in proceeds. Following the sale of shares at $13.45 each, the insider now holds 39,728 shares.
Before that, Piekos Brian had sold 4,471 shares from its account. In a trade valued at $60,139, the Chief Financial Officer traded KalVista Pharmaceuticals Inc shares for $13.45 each. Upon closing the transaction, the insider’s holdings decreased to 4,471 shares, worth approximately $0.16 million.
As published in a research note from Needham on January 09, 2026, KalVista Pharmaceuticals Inc [KALV] has been retained to a Buy and the price target has been revised to $35. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in early January. As of January 31, 2025, JMP Securities has initiated its “Mkt outperform” rating for KALV. Earlier on January 07, 2025, TD Cowen initiated its rating. Their recommendation was “a Buy” for KALV stock.
Analyzing KALV Stock Performance
On last trading session, KalVista Pharmaceuticals Inc [NASDAQ: KALV] plunged -1.84% to $14.96. The stock’s lowest price that day was $14.7, but it reached a high of $15.435 in the same session. During the last five days, there has been a drop of approximately -5.44%. Over the course of the year, KalVista Pharmaceuticals Inc shares have jumped approximately 102.16%.
Support And Resistance Levels for KalVista Pharmaceuticals Inc (KALV)
RSI (Relative Strength Index) is 46.33 on the 14-day chart, showing neutral technical sentiment.
Is KalVista Pharmaceuticals Inc subject to short interest?
Stocks of KalVista Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 2.49 million shares to 16.91 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 14.43 million shares. A jump of 14.7% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.99 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.99.
Which companies own the most shares of KalVista Pharmaceuticals Inc (KALV)?
In terms of KalVista Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 32 in the next 12 months, up nearly 109.97% from the previous closing price of $15.24. Analysts anticipate KalVista Pharmaceuticals Inc stock to reach 37 by 2026, with the lowest price target being 28. In spite of this, 2 analysts ranked KalVista Pharmaceuticals Inc stock as Buy at the end of 2026. On December 18, 2024, BofA Securities assigned a price target of “a Buy” to the stock and initiated coverage with a $22.
